研發與技術
R&D and Technology
The first Chinese national standards for SARS-CoV- neutralizing antibody
2021-08-30
999+
學術論著
上一篇：Safety tolerability pharmacokinetics and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: A randomized double-blind placebo-controlled phase I study
下一篇：Pharmacokinetic efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A
最新資訊
-
2024-SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma A randomized phase 3 trial
2024-06-20 -
2024-Rapid development and mass production of SARS-CoV-2 neutralizing chicken egg yolk antibodies with protective efficacy in hamsters
2024-05-06 -
2024-Immunogenicity of Tetravalent Protein Vaccine against SARS-CoV-2 EG.5 Subvaraint A Phase 2 Trial
2024-02-08 -
2024-Finotonlimab with chemotherapy in recurrent or static head and neck cancer a randomized phase 3 trial
2024-06-02